Chunliang Jiang

Title: Innovations in Pharmaceutical Composition by Chunliang Jiang

Introduction

Chunliang Jiang is a notable inventor based in Tianjin, China. He has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment of sepsis. His innovative work has led to the development of effective drug formulations that are both safe and efficacious.

Latest Patents

Chunliang Jiang holds a patent for a pharmaceutical composition aimed at treating sepsis. This patent includes a three-component formulation consisting of hydroxysafflower yellow A (HSYA), paeoniflorin, and albiflorin. Additionally, he has developed a seven-component pharmaceutical composition that incorporates HSYA, paeoniflorin, albiflorin, oxypaeoniflorin, senkyunolide I, salvianic acid A sodium (SAAS), and ferulic acid. Both formulations have been verified at the cellular and animal levels for their efficacy in treating sepsis, while also demonstrating safety in drug toxicity experiments. This pharmaceutical composition serves as an active ingredient in the Xuebijing Injection, which is utilized for clinical treatment of sepsis.

Career Highlights

Chunliang Jiang is associated with Tianjin Chase Sun Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its potential impact on the treatment of serious medical conditions.

Collaborations

Chunliang Jiang collaborates with esteemed colleagues such as Yang Yu and Jianli Wang, contributing to a dynamic research environment that fosters innovation in pharmaceutical sciences.

Conclusion

Chunliang Jiang's contributions to pharmaceutical compositions highlight his commitment to improving treatment options for sepsis. His innovative formulations and collaborative efforts position him as a key figure in the field of pharmaceutical research.